Skip to main content

Table 5 Effect of genetic polymorphisms and smoking histories of participants on nicotine dependence in current smokers: Odds ratios for the SLC6A3 , ANKK1/DRD2 , and CYP2A6 genotypes in current smokers with nicotine dependence

From: Genetic influence of dopamine receptor, dopamine transporter, and nicotine metabolism on smoking cessation and nicotine dependence in a Japanese population

Genotype Number OR (95% CI) P value
SLC6A3 10r/10r 9/52, 8/49 0.130 (0.036–0.464), 0.117 (0.030–0.459) 0.002, 0.003
  10r/# or #/# 8/6, 7/5
ANKK1/DRD2 A2/A2 4/23, 4/21 0.468 (0.136–1.615), 0.571 (0.161–2.032) 0.352, 0.570
  A2/A1 or A1/A1 13/35, 11/33
CYP2A6 *1/*1 15/39, 13/36 3.654 (0.757–17.634), 3.250 (0.661–15.979) 0.165, 0.235
  *1/*4 or *4/*4 2/19, 2/18
  1. Each analysis was performed for the whole cohort (the left side) and the male subgroup only (the right side). #DAT alleles with less than 10 repeats. Number, numbers of subjects respectively indicated with high (≥ 4) per low scores (< 4) of HSI, Heavy Smoking Index (summary score of the number of cigarettes smoked per day and the time to the first cigarette of the day extracted from the Fagerstrom Test for Nicotine Dependence) in current smokers; OR, odds ratio; CI, confidence interval.